{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:03:13Z","timestamp":1791306193742,"version":"4.3.1"},"reference-count":199,"publisher":"American Chemical Society (ACS)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Chem."],"published-print":{"date-parts":[[2014,9,11]]},"DOI":"10.1021\/jm5003952","type":"journal-article","created":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T16:55:32Z","timestamp":1400691332000},"page":"7160-7181","source":"Crossref","is-referenced-by-count":163,"title":["Serotonin 5-HT<sub>6<\/sub>Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer\u2019s Disease"],"prefix":"10.1021","volume":"57","author":[{"given":"Bellinda","family":"Benham\u00fa","sequence":"first","affiliation":[{"name":"Departamento de Qu\u00edmica Org\u00e1nica I, Facultad de Ciencias Qu\u00edmicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Mart\u00edn-Fontecha","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Org\u00e1nica I, Facultad de Ciencias Qu\u00edmicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henar","family":"V\u00e1zquez-Villa","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Org\u00e1nica I, Facultad de Ciencias Qu\u00edmicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Pardo","sequence":"additional","affiliation":[{"name":"Laboratori de Medicina Computacional, Unitat de Bioestad\u00edstica, Facultat de Medicina, Universitat Aut\u00f2noma de Barcelona, E-08193 Bellaterra, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda L.","family":"L\u00f3pez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Org\u00e1nica I, Facultad de Ciencias Qu\u00edmicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2014,6,3]]},"reference":[{"key":"ref1\/cit1","unstructured":"Global Health and Aging (2011, publication by the National Institute on Aging and National Institutes of Health).http:\/\/www.who.int\/ageing\/publications\/global_health.pdf(accessed May 14, 2014) ."},{"key":"ref2\/cit2","unstructured":"Alzheimer\u2019s Disease International: World Alzheimer Report 2013.http:\/\/www.alz.co.uk\/research\/WorldAlzheimerReport2013.pdf(accessed May 14, 2014) ."},{"key":"ref3\/cit3","unstructured":"Medicines in Development. Alzheimer\u2019s Disease (2013, report published by the Pharmaceutical Research and Manufacturers of America (PhRMA)).http:\/\/www.phrma.org\/sites\/default\/files\/Alzheimer%27s%202013.pdf(accessed May 14, 2014) ."},{"key":"ref4\/cit4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","volume":"362","author":"Querfurth H. W.","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref5\/cit5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1042\/BST0380993","volume":"38","author":"LaFerla F. M.","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"ref6\/cit6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(03)00502-7","volume":"2","author":"Scarpini E.","year":"2003","journal-title":"Lancet Neurol."},{"key":"ref7\/cit7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"Mangialasche F.","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref8\/cit8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tips.2010.12.007","volume":"32","author":"Palmer A. M.","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"ref9\/cit9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0149-2918(04)90064-1","volume":"26","author":"Standridge J. B.","year":"2004","journal-title":"Clin. Ther."},{"key":"ref10\/cit10","first-page":"367","volume":"4","author":"Thomas S. J.","year":"2009","journal-title":"Clin. Interventions Aging"},{"key":"ref11\/cit11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2174\/156802608785161420","volume":"8","author":"Geldenhuys W. J.","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"ref12\/cit12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1124\/pr.108.000562","volume":"61","author":"Buckingham S. D.","year":"2009","journal-title":"Pharmacol. Rev."},{"key":"ref13\/cit13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156802610790410983","volume":"10","author":"Haydar S. N.","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"ref14\/cit14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.bcp.2011.06.039","volume":"82","author":"Parri H. R.","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref15\/cit15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.drudis.2013.09.005","volume":"18","author":"Melancon B. J.","year":"2013","journal-title":"Drug Discovery Today"},{"key":"ref16\/cit16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/clpt.2010.165","volume":"88","author":"Carter M. D.","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref17\/cit17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pbb.2011.02.002","volume":"99","author":"Terry A. V.","year":"2011","journal-title":"Pharmacol., Biochem. Behav."},{"key":"ref18\/cit18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1755-5949.2010.00161.x","volume":"17","author":"Mitchell R. A.","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref19\/cit19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainresbull.2010.11.004","volume":"84","author":"Yu J. T.","year":"2011","journal-title":"Brain Res. Bull."},{"key":"ref20\/cit20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.02.002","volume":"97","author":"Xu Y. Q.","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"ref21\/cit21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.06.010","volume":"99","author":"Rodriguez J. J.","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"ref22\/cit22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/11590190-000000000-00000","volume":"25","author":"Geldenhuys W. J.","year":"2011","journal-title":"CNS Drugs"},{"key":"ref23\/cit23","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr078224o","volume":"108","author":"Nichols D. E.","year":"2008","journal-title":"Chem. Rev."},{"key":"ref24\/cit24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","volume":"29","author":"King M. V.","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref25\/cit25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pbb.2010.12.021","volume":"98","author":"Borsini F.","year":"2011","journal-title":"Pharmacol., Biochem. Behav."},{"key":"ref26\/cit26","first-page":"371","volume":"20","author":"Marazziti D.","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref27\/cit27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pharmthera.2007.08.006","volume":"117","author":"Heal D. J.","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"ref28\/cit28","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1734-1140(10)70315-7","volume":"62","author":"Wesolowska A.","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"ref29\/cit29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.drudis.2006.02.004","volume":"11","author":"Holenz J.","year":"2006","journal-title":"Drug Discovery Today"},{"key":"ref30\/cit30","first-page":"642","volume":"11","author":"Johnson C. N.","year":"2008","journal-title":"Curr. Opin. Drug Discovery Dev."},{"key":"ref31\/cit31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nurt.2008.05.008","volume":"5","author":"Upton N.","year":"2008","journal-title":"Neurotherapeutics"},{"key":"ref32\/cit32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1586\/ern.09.51","volume":"9","author":"Geldenhuys W. J.","year":"2009","journal-title":"Exp. Rev. Neurother."},{"key":"ref33\/cit33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ddr.20293","volume":"70","author":"Liu K. G.","year":"2009","journal-title":"Drug Dev. Res."},{"key":"ref34\/cit34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1358\/dof.2009.34.12.1416986","volume":"34","author":"Wilson C.","year":"2009","journal-title":"Drugs Future"},{"key":"ref35\/cit35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/156802610790411036","volume":"10","author":"Ross\u00e9 G.","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"ref36\/cit36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-385902-0.00002-4","volume":"96","author":"Meneses A.","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"ref37\/cit37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2011.01.004","volume":"11","author":"Codony X.","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref38\/cit38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/alzrt169","volume":"5","author":"Ramirez M. J.","year":"2013","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref39\/cit39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0026-895X(25)13616-X","volume":"43","author":"Monsma F. J.","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"ref40\/cit40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/bbrc.1993.1619","volume":"193","author":"Ruat M.","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref41\/cit41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1471-4159.1996.66010047.x","volume":"66","author":"Kohen R.","year":"1996","journal-title":"J. Neurochem."},{"key":"ref42\/cit42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature11896","volume":"494","author":"Venkatakrishnan A. J.","year":"2013","journal-title":"Nature"},{"key":"ref43\/cit43","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1126\/science.1232808","volume":"340","author":"Wacker D.","year":"2013","journal-title":"Science"},{"key":"ref44\/cit44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0006-8993(96)01224-3","volume":"746","author":"Gerard C.","year":"1997","journal-title":"Brain Res."},{"key":"ref45\/cit45","first-page":"S68","volume":"21","author":"Hamon M.","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref46\/cit46","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1124\/mol.64.6.1295","volume":"64","author":"Hirst W. D.","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref47\/cit47","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/mol.64.6.1277","volume":"64","author":"Setola V.","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref48\/cit48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0022-3565(25)10539-9","volume":"274","author":"Bourson A.","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref49\/cit49","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00056-9","volume":"41","author":"Woolley M. L.","year":"2001","journal-title":"Neuropharmacology"},{"key":"ref50\/cit50","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/sj.bjp.0701851","volume":"124","author":"Sleight A. J.","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"ref51\/cit51","unstructured":"Bromidge, S. M.; King, F. D.; Wyman, P. A.Preparation ofN-(piperazinylphenyl)arylsulfonamides as CNS agents. PCT Int. Appl. WO9827081 A1, 1998."},{"key":"ref52\/cit52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1021\/jm980532e","volume":"42","author":"Bromidge S. M.","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref53\/cit53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00213-003-1552-5","volume":"170","author":"Woolley M. L.","year":"2003","journal-title":"Psychopharmacology"},{"key":"ref54\/cit54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.npp.1300332","volume":"29","author":"Foley A. G.","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"ref55\/cit55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1098-2396(199607)23:3<164::AID-SYN5>3.0.CO;2-6","volume":"23","author":"Gerard C.","year":"1996","journal-title":"Synapse"},{"key":"ref56\/cit56","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/jm021085c","volume":"46","author":"Riemer C.","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref57\/cit57","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1460-9568.2006.05003.x","volume":"24","author":"Marcos B.","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"ref58\/cit58","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0893-133X(01)00265-2","volume":"25","author":"Dawson L. A.","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"ref59\/cit59","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/sj.npp.1301503","volume":"33","author":"Schechter L. E.","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref60\/cit60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2004.03.012","volume":"47","author":"King M. V.","year":"2004","journal-title":"Neuropharmacology"},{"key":"ref61\/cit61","first-page":"59","volume":"3","author":"Woolley M. L.","year":"2004","journal-title":"Curr. Drug Targets: CNS Neurol. Disord."},{"key":"ref62\/cit62","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.neuroscience.2009.07.061","volume":"164","author":"West P. J.","year":"2009","journal-title":"Neuroscience"},{"key":"ref63\/cit63","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0165-0173(02)00268-0","volume":"41","author":"Myhrer T.","year":"2003","journal-title":"Brain Res. Rev."},{"key":"ref64\/cit64","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1017\/S146114570999054X","volume":"13","author":"Marcos B.","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref65\/cit65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.nlm.2009.08.009","volume":"93","author":"Huerta-Rivas A.","year":"2010","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref66\/cit66","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/sj.npp.1301284","volume":"32","author":"Mitchell E. S.","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref67\/cit67","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.npp.1300330","volume":"29","author":"Garcia-Alloza M.","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"ref68\/cit68","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0304-3940(99)00802-2","volume":"276","author":"Tsai S. J.","year":"1999","journal-title":"Neurosci. Lett."},{"key":"ref69\/cit69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0304-3940(02)00221-5","volume":"325","author":"Orlacchio A.","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref70\/cit70","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.pharmthera.2005.05.001","volume":"108","author":"Mitchell E. S.","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"ref71\/cit71","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1097\/00001756-199412000-00037","volume":"5","author":"Sebben M.","year":"1994","journal-title":"NeuroReport"},{"key":"ref72\/cit72","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(03)01855-7","volume":"472","author":"Zhang J. Y.","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"ref73\/cit73","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1074\/jbc.M606215200","volume":"282","author":"Yun H. M.","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref74\/cit74","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.npp.1301294","volume":"32","author":"Bonsi P.","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref75\/cit75","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/sj.bjp.0703458","volume":"130","author":"Hirst W. D.","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref76\/cit76","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.neuropharm.2008.06.061","volume":"55","author":"Fone K. C. F.","year":"2008","journal-title":"Neuropharmacology"},{"key":"ref77\/cit77","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","volume":"268","author":"Roth B. L.","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref78\/cit78","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1124\/mol.52.3.515","volume":"52","author":"Boess F. G.","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"ref79\/cit79","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1517\/13543776.12.4.513","volume":"12","author":"Slassi A.","year":"2002","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref80\/cit80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1358\/dof.2005.030.05.907630","volume":"30","author":"Davies S. L.","year":"2005","journal-title":"Drugs Future"},{"key":"ref81\/cit81","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jlcr.3001","volume":"56","author":"Zimmer L.","year":"2013","journal-title":"J. Labelled Compd. Radiopharm."},{"key":"ref82\/cit82","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11307-011-0523-1","volume":"14","author":"Comley R. A.","year":"2012","journal-title":"Mol. Imaging Biol."},{"key":"ref83\/cit83","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1021\/jm1007177","volume":"53","author":"V\u00e1zquez-Villa H.","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref84\/cit84","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1021\/jm990550b","volume":"43","author":"Glennon R. A.","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref85\/cit85","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0960-894X(00)00453-4","volume":"10","author":"Tsai Y.","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref86\/cit86","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1021\/jm010943m","volume":"44","author":"Russell M. G.","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref87\/cit87","first-page":"163","volume-title":"Progress in Medicinal Chemistry","volume":"48","author":"Witty D.","year":"2009","edition":"1"},{"key":"ref88\/cit88","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/156802610791111542","volume":"10","author":"Glennon R. A.","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"ref89\/cit89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-384976-2.00001-0","volume":"94","author":"Liu K. G.","year":"2010","journal-title":"Int. Rev. Neurobiol."},{"key":"ref90\/cit90","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1517\/13543776.2012.709236","volume":"22","author":"Ivachtchenko A. V.","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref91\/cit91","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1573407211309010007","volume":"9","author":"Ivachtchenko A. V.","year":"2013","journal-title":"Curr. Bioact. Compd."},{"key":"ref92\/cit92","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1021\/jm050247c","volume":"48","author":"L\u00f3pez-Rodr\u00edguez M. L.","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref93\/cit93","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1021\/jm060469q","volume":"49","author":"Sikazwe D.","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref94\/cit94","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1021\/ci700160t","volume":"48","author":"Kim H. J.","year":"2008","journal-title":"J. Chem. Inf. Model."},{"key":"ref95\/cit95","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1016\/j.bmcl.2004.05.076","volume":"14","author":"Pullagurla M. R.","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref96\/cit96","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/jm070910s","volume":"51","author":"Dukat M.","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref97\/cit97","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1021\/jm901672k","volume":"53","author":"de la Fuente T.","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref98\/cit98","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1046\/j.1471-4159.1998.71052169.x","volume":"71","author":"Boess F. G.","year":"1998","journal-title":"J. Neurochem."},{"key":"ref99\/cit99","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0960-894X(02)00172-5","volume":"12","author":"Bromidge S. M.","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref100\/cit100","unstructured":"Nordvall, G.; Petersson, C.; Sehgelmeble, F.Benzoxazepinylbenzenesulfonamide and process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-HT6mediated disorders such as Alzheimer\u2019s disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson\u2019s disease. PCT Int. Appl. WO2007004959 A1, 2007."},{"key":"ref101\/cit101","doi-asserted-by":"crossref","first-page":"9255","DOI":"10.1021\/jm300955x","volume":"55","author":"Nirogi R.","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref102\/cit102","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0960-894X(00)00597-7","volume":"11","author":"Bromidge S. M.","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref103\/cit103","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2006.09.049","volume":"553","author":"Hirst W. D.","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref104\/cit104","unstructured":"Nordvall, G.; Petersson, C.; Rakos, L.; Sohn, D.Novel 8-sulfonyl-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5-HT6receptor and their preparation and pharmaceutical compositions. PCT Int. Appl. WO2006126938 A1, 2006."},{"key":"ref105\/cit105","unstructured":"MacDonald, G. J.; Thompson, M.Preparation of novel phenyl sulfone derivatives and their use in the treatment of CNS disorders. PCT. Int. Appl. WO2004080986 A1, 2004."},{"key":"ref106\/cit106","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.1021\/jm200466r","volume":"54","author":"van Loevezijn A.","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref107\/cit107","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.nlm.2011.06.015","volume":"96","author":"de Bruin N. M. W. J.","year":"2011","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref108\/cit108","first-page":"230","volume":"10","author":"Lee M.","year":"2000","journal-title":"Med. Chem. Res."},{"key":"ref109\/cit109","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1016\/j.bmcl.2006.08.068","volume":"16","author":"Kolanos R.","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref110\/cit110","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1016\/j.bmcl.2008.06.030","volume":"18","author":"Liu K. G.","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref111\/cit111","unstructured":"Slassi, A.; Edwards, L.; O\u2019Brien, A.; Xin, T.; Tehim, A.Preparation of 3-(2-pyrrolidinylmethyl)indoles as 5-HT6antagonists. PCT Int. Appl. WO9947516 A1, 1999."},{"key":"ref112\/cit112","unstructured":"Slassi, A.; Edwards, L.; O\u2019Brien, A.; Xin, T.; Tehim, A.Preparation of 1-(arylsulfonyl)-3-(tetrahydropyridinyl)indoles as 5-HT6receptor inhibitors. U.S. Pat. Appl. US6133287A, 2000."},{"key":"ref113\/cit113","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bmcl.2004.10.064","volume":"15","author":"Cole D. C.","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref114\/cit114","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/jm049615n","volume":"48","author":"Holenz J.","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref115\/cit115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1021\/jm049243i","volume":"48","author":"Cole D. C.","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref116\/cit116","unstructured":"Briggs, A. J.; Clark, R. D.; Harris, R. N., III; Repke, D. B.; Wren, D. L.Preparation of 4-piperazinylindoles with 5-HT6receptor affinity. PCT Int. Appl. WO2002102774 A1, 2002."},{"key":"ref117\/cit117","unstructured":"Bromidge, S. M.Preparation of 4-piperazinoindoles for treating CNS disorders. PCT Int. Appl. WO2002041889 A2, 2002."},{"key":"ref118\/cit118","unstructured":"Caldirola, P.; Johansson, G.; Nilsson, B. M.2- 3- 4- or 5-Substituted-1-(benzenesulfonyl)indoles and their use in therapy. PCT Int. Appl. WO2002032863 A1, 2002."},{"key":"ref119\/cit119","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.bmcl.2005.06.107","volume":"15","author":"Ahmed M.","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref120\/cit120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.euroneuro.2006.06.009","volume":"17","author":"Schreiber R.","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref121\/cit121","unstructured":"Beard, C. C.; Clark, R. D.; Fisher, L. E.; Harris, R. N., III; Repke, D. B.Preparation of new indole derivatives with 5-HT6receptor affinity. PCT Int. Appl. WO2002098857 A1, 2002."},{"key":"ref122\/cit122","unstructured":"Madera, A. M.; Weikert, R. J.Preparation of 2,7-substituted indoles as 5-HT6modulators. PCT Int. Appl. WO2004026830 A1, 2004."},{"key":"ref123\/cit123","unstructured":"Bernotas, R. C.; Lenicek, S. E.Preparation of 1-heterocyclylalkyl-3-sulfonylindoles and indazoles as 5-HT6ligands. PCT Int. Appl. WO2004009548 A1, 2004."},{"key":"ref124\/cit124","unstructured":"Zhao, S.H.Preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6antagonists, for treating CNS disorders. PCT Int. Appl. WO2004050085 A1, 2004."},{"key":"ref125\/cit125","unstructured":"Filla, S. A.; Flaugh, M. E.; Gillig, J. R.; Heinz, L. J.; Krushinski, J. H., Jr.; Liu, B. X.; Pineiro-Nunez, M. M.; Schaus, J. M.; Ward, J. S.Preparation of benzenesulfonic acid indol-5-yl esters as antagonists of the 5-HT6receptor. PCT Int. Appl. WO2002060871 A2, 2002."},{"key":"ref126\/cit126","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1016\/j.bmcl.2012.10.057","volume":"22","author":"Nirogi R. V. S.","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref127\/cit127","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.bmcl.2012.01.022","volume":"22","author":"Henderson A. J.","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref128\/cit128","unstructured":"Johansson, G.; Jenmalm-Jensen, A.; Beierlein, K.Preparation of pyridino-fused heterocycles useful for the treatment of obesity, type II diabetes and CNS disorders. PCT Int. Appl. WO2004000828 A1, 2003."},{"key":"ref129\/cit129","unstructured":"Boes, M.; Riemer, C.; Stadler, H.Preparation of pyrazolopyrimidines and pyrazolotriazines with 5-HT6receptor affinity. Eur. Pat. Appl. EP941994 A1, 1999."},{"key":"ref130\/cit130","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1021\/jm1007825","volume":"53","author":"Liu K. G.","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref131\/cit131","unstructured":"Elokdah, H. M.; Greenfield, A. A.; Liu, K.; McDevitt, R. E.; McFarlane, G. R.; Grosanu, C.; Lo, J. R.; Li, Y.; Robichaud, A. J.; Bernotas, R. C.Preparation of substituted-3-sulfonylindazole derivatives as 5-HT6receptor modulators for treating CNS disorders. U.S. Pat. Appl. US20070037802 A1, 2007."},{"key":"ref132\/cit132","unstructured":"Haydar, S. N.; Andrae, P. M.; Yun, H.; Robichaud, A. J.1-(Arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds as 5-hydroxytryptamine-6 receptor ligands and their preparation and use in the treatment of diseases. U.S. Pat. Appl. US20100120779 A1, 2010."},{"key":"ref133\/cit133","unstructured":"Cole, D. C.Preparation ofN-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands. PCT Int. Appl. WO2005012311 A1, 2005."},{"key":"ref134\/cit134","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1021\/jm100350r","volume":"53","author":"Ivachtchenko A. V.","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref135\/cit135","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1021\/jm201079g","volume":"54","author":"Ivachtchenko A. V.","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref136\/cit136","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1016\/j.bmcl.2012.05.036","volume":"22","author":"Ivachtchenko A. V.","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref137\/cit137","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.ejmech.2011.01.038","volume":"46","author":"Ivachtchenko A. V.","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref138\/cit138","unstructured":"Cole, D. C.; Bernotas, R. C.Preparation of arylsulfonyldihydrobenzimidazolones as serotonin 5-HT6receptor ligands. U.S. Pat. Appl. US20050020575 A1, 2005."},{"key":"ref139\/cit139","unstructured":"Putman, D. G.Preparation of 2,5- and 2,6-substituted tetrahydroisoquinolines as 5-HT6modulators, in particular selective 5-HT6antagonists, for treating CNS disorders. PCT Int. Appl. WO2004078176 A1, 2004."},{"key":"ref140\/cit140","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1016\/j.bmcl.2006.12.093","volume":"17","author":"Zhao S.-H.","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref141\/cit141","unstructured":"Caldirola, P.; Johansson, G.; Sutin, L.Benzofuranyl derivatives as 5-HT6receptor inhibitors, and therapeutic uses. PCT Int. Appl. WO2006134150 A1, 2006."},{"key":"ref142\/cit142","unstructured":"Greenblatt, L. P.Preparation of piperidinylchromenylsulfonamides as 5-HT6ligands. PCT Int. Appl. WO2005037830 A1, 2005."},{"key":"ref143\/cit143","unstructured":"Krauss, N. E.; Zhao, S.H.Preparation of chroman derivatives as 5-HT receptor ligands. PCT Int. Appl. WO2006066756 A1, 2006."},{"key":"ref144\/cit144","unstructured":"Berger, J.; Zhao, S.H.Preparation of arylsulfonyl benzodioxanes for modulating 5-HT6receptor, 5-HT2Areceptor or both. PCT Int. Appl. WO2005105776 A1, 2005."},{"key":"ref145\/cit145","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.bmcl.2011.12.026","volume":"22","author":"Tripathy R.","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref146\/cit146","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.bmcl.2005.01.031","volume":"15","author":"Lee M.","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref147\/cit147","unstructured":"Greenhouse, R.; Harris, R. N., III; Jaime-Figueroa, S.; Kress, J. M.; Repke, D. B.; Stabler, R. S.Preparation of tetralin and indane derivatives and use as selective 5-HT6and 5-HT2Areceptor antagonists for treatment of CNS disorders. PCT Int. Appl. WO2006066790 A1, 2006."},{"key":"ref148\/cit148","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1021\/jm900796p","volume":"52","author":"Mesquida N.","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref149\/cit149","unstructured":"Becker, O.; Lobera, M.; Melendez, R. E.; Sharadendu, A.; Wu, L.; Yu, X. Y.; Dhanoa, D. S.; Cheruku, S. R.; Marantz, Y.; Noiman, S.; Fichman, M.; Senderowitz, H.; Shacham, S.; Saha, A.; Orbach, P.Preparation of piperazinylarylamines as 5-HT6modulators. PCT Int. Appl. WO2006081332 A1, 2006."},{"key":"ref150\/cit150","unstructured":"Tenbrink, R. E.Preparation of oxazinocarbazoles as 5-HT6serotonin receptor modulators. PCT Int. Appl. WO2001009142 A1, 2001."},{"key":"ref151\/cit151","unstructured":"Kelly, M. G.; Greenblatt, L. P.; Zhang, G.; Palmer, Y. L.; Lenicek, S. E.Preparation of 2-(aminoalkyl)chromans and benzofurans as 5-hydroxytryptamine-6 ligands for treatment of CNS disorders. PCT Int. Appl. WO2003029239 A1, 2003."},{"key":"ref152\/cit152","unstructured":"Harris, R. N., III; Kress, J. M.; Repke, D. B.; Stabler, R. S.Preparation of aryloxy quinolines as 5-HT6receptor antagonists. U.S. Pat. Appl. US20070027161 A1, 2007."},{"key":"ref153\/cit153","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1017\/S1461145710000659","volume":"13","author":"Arnt J.","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref154\/cit154","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.bmcl.2009.03.077","volume":"19","author":"Singer J. M.","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref155\/cit155","unstructured":"Harris, R. N., III; Repke, D. B.; Stabler, R. S.Preparation of quinolinone and benzoxazinone derivatives as 5-HT6modulators. PCT Int. Appl. WO2004080969 A1, 2004."},{"key":"ref156\/cit156","unstructured":"Maag, H.; Sui, M.; Zhao, S.H.Preparation of substituted benzoxazinones as selective 5-HT6antagonists for treating central nervous system diseases and gastrointestinal tract disorders. U.S. Pat. Appl. US20040092512 A1, 2004."},{"key":"ref157\/cit157","unstructured":"Harris, R. N., III; Kress, J. M.; Repke, D. B.; Stabler, R. S.Dibenzoxazepinone derivatives as 5-HT6and 5-HT2Areceptor antagonists, their preparation, pharmaceutical compositions, and use in therapy. PCT Int. Appl. WO2006061126 A2, 2006."},{"key":"ref158\/cit158","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bmcl.2007.11.045","volume":"18","author":"Seong C. M.","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref159\/cit159","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.bmcl.2014.03.049","volume":"24","author":"Hostetler G.","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref160\/cit160","unstructured":"Cole, D. C.; Kelly, M. G.; Bravo, B. A.; Palmer, Y. L.Preparation of 1-(indol-3-yl)alkylidenehydrazine carboximidamides as 5-hydroxytryptamine-6 ligands. U.S. Pat. Appl. US20030232843 A1, 2003."},{"key":"ref161\/cit161","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/cbdd.12279","volume":"83","author":"Hostetler G.","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"ref162\/cit162","unstructured":"Ivashchenko, A. A.; Ivashchenko, A. V.; Lavrovsky, Y. V.; Mitkin, O. D.; Savchuk, N. F.; Tkachenko, S. Y.; Okun, I. M.Preparation of 1,2,3,4-tetrahydro-1H-pyrido[4,3-b]indoles and 1,2,3,4,5,6-hexahydroazepino[4,3-b]indoles as ligands for \u03b1-adrenoceptors and for dopamine, histamine, imidazoline and serotonin receptors and their use in treatment of CNS diseases. PCT Int. Appl. WO2009082268 A2, 2009."},{"key":"ref163\/cit163","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.bcp.2009.06.021","volume":"78","author":"Schaffhauser H.","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref164\/cit164","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"Shahid M.","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"ref165\/cit165","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/sj.bjp.0703457","volume":"130","author":"Routledge C.","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref166\/cit166","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s002130100840","volume":"158","author":"Rogers D. C.","year":"2001","journal-title":"Psychopharmacology"},{"key":"ref167\/cit167","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/1568026023393877","volume":"2","author":"Russell M. G. N.","year":"2002","journal-title":"Curr. Top. Med. Chem."},{"key":"ref168\/cit168","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1124\/jpet.103.056002","volume":"307","author":"Lindner M. D.","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref169\/cit169","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-4328(00)00316-8","volume":"118","author":"Meneses A.","year":"2001","journal-title":"Behav. Brain Res."},{"key":"ref170\/cit170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00213-005-2261-z","volume":"181","author":"Hatcher P. D.","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref171\/cit171","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.pbb.2005.05.005","volume":"81","author":"Perez-Garcia G.","year":"2005","journal-title":"Pharmacol., Biochem. Behav."},{"key":"ref172\/cit172","first-page":"150","volume":"101","author":"King M. V.","year":"2006","journal-title":"J. Pharmacol. Sci."},{"key":"ref173\/cit173","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bjp.2008.281","volume":"155","author":"Marcos B.","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref174\/cit174","unstructured":"Studies found in clinical trials for SB-742457:http:\/\/clinicaltrials.gov\/ct2\/results?term=SB-742457+&Search=Search(accessed May 14, 2014) ."},{"key":"ref175\/cit175","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2174\/156720510791383831","volume":"7","author":"Maher-Edwards G.","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"ref176\/cit176","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/gps.2562","volume":"26","author":"Maher-Edwards G.","year":"2011","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref177\/cit177","unstructured":"GlaxoSmithKline study AZ3110865 of compound SB-742457, September 21, 2011:http:\/\/www.gsk-clinicalstudyregister.com\/study\/AZ3110865#rs(accessed May 14, 2014) ."},{"key":"ref178\/cit178","unstructured":"GlaxoSmithKline study AZ3110866 of compound SB-742457, September 21, 2011:http:\/\/www.gsk-clinicalstudyregister.com\/study\/AZ3110866#rs(accessed May 14, 2014) ."},{"key":"ref179\/cit179","unstructured":"GlaxoSmithKline Product Development Pipeline 2013. February, 2013.http:\/\/www.gsk.com\/content\/dam\/gsk\/globals\/documents\/pdf\/GSK%202013%20Pipeline.pdf(accessed May 14, 2014) ."},{"key":"ref180\/cit180","unstructured":"Studies found in clinical trials for SAM-315:http:\/\/clinicaltrials.gov\/ct2\/results?term=sam-315&Search=Search(accessed May 14, 2014) ."},{"key":"ref181\/cit181","unstructured":"Studies found in clinical trials for SAM-531:http:\/\/clinicaltrials.gov\/ct2\/results?term=sam-531&Search=Search(accessed May 14, 2014) ."},{"key":"ref182\/cit182","unstructured":"Studies found in clinical trials for SRA-444:http:\/\/clinicaltrials.gov\/ct2\/results?term=sra-444&Search=Search(accessed May 14, 2014) ."},{"key":"ref183\/cit183","unstructured":"Studies found in clinical trials for dimebolin:http:\/\/clinicaltrials.gov\/ct2\/results?term=dimebolin&Search=Search(accessed May 14, 2014) ."},{"key":"ref184\/cit184","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","volume":"372","author":"Doody R. S.","year":"2008","journal-title":"Lancet"},{"key":"ref185\/cit185","unstructured":"Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon in Alzheimer\u2019s Disease. January 16, 2012.http:\/\/www.pfizer.com\/news\/press-release\/press-release-archive-detail\/medivation_and_pfizer_announce_results_from_phase_3_concert_trial_of_dimebon_in_alzheimer_s_disease(accessed May 14, 2014) ."},{"key":"ref186\/cit186","unstructured":"EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6Drug Candidate. April 18, 2007.http:\/\/www.drugs.com\/clinical_trials\/epix-pharmaceuticals-announces-statistically-significant-results-cognitive-function-phase-1b-645.html(accessed May 14, 2014) ."},{"key":"ref187\/cit187","unstructured":"EPIX Pharmaceuticals Announces Discontinuation of PRX-00023 Clinical Development Program. March 20, 2008.http:\/\/www.reuters.com\/article\/2008\/03\/20\/idUS99490+20-Mar-2008+BW20080320(accessed May 14, 2014) ."},{"key":"ref188\/cit188","unstructured":"Roche Full Year 2005. Presentation to Analysts. February, 2006.http:\/\/www.roche.com\/irp060201.pdf(accessed May 14, 2014) ."},{"key":"ref189\/cit189","unstructured":"SYN120 for the treatment of Alzheimer\u2019s disease and other cognitive disorders.http:\/\/www.biotie.com\/en\/investors\/releases\/release?NewsItemID=1478642&NewsItemYear=2011(accessed May 14, 2014) ."},{"key":"ref190\/cit190","unstructured":"Studies found in clinical trials for ABT-354:http:\/\/clinicaltrials.gov\/ct2\/results?term=abt-354&Search=Search(accessed May 14, 2014) ."},{"key":"ref191\/cit191","unstructured":"Suven Presented Positive Phase-I Clinical Data of SUVN-502 for Alzheimer\u2019s Disease at ICAD 2009, Vienna, Austria. July 27, 2009.http:\/\/suven.com\/news_July2009_27.htm(accessed May 14, 2014) ."},{"key":"ref192\/cit192","unstructured":"Suven\u2019s Alzheimer Drug Candidate SUVN-502 Successfully Completed All Chronic Toxicological (Tox) Studies and Demonstrated Very High Margin of Safety (MOS). May 18, 2011.http:\/\/www.suven.com\/news_May2011_18.htm(accessed May 14, 2014) ."},{"key":"ref193\/cit193","unstructured":"Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase II Clinical Studies. February 1, 2010.http:\/\/www.avineuro.com\/avineuro-pharmaceuticals-inc-announces-beginning-of-phase-ii-clinical-studies-of-avn-101-potent-small-molecule-for-treatment-of-alzheimer%E2%80%99s-disease-and-anxiety\/(accessed May 14, 2014) ."},{"key":"ref194\/cit194","unstructured":"News and Events (Avineuro Pharmaceuticals, Inc. reports positive phase I clinical trial results on AVN-322, potent small molecule for the treatment of Alzheimer\u2019s disease). March 1st, 2010.http:\/\/www.avineuro.com\/avineuro-pharmaceuticals-inc-reports-positive-phase-i-clinical-trial-results-on-avn-322-potent-small-molecule-for-treatment-of-alzheimer%E2%80%99s-disease\/(accessed May 14, 2014) ."},{"key":"ref195\/cit195","unstructured":"Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase IIb Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia. July 15, 2013.http:\/\/www.avineuro.com\/category\/news\/(accessed May 14, 2014) ."},{"key":"ref196\/cit196","unstructured":"Studies found in clinical trials for PF-05212377:http:\/\/clinicaltrials.gov\/ct2\/results?term=PF-05212377+&Search=Search(accessed May 14, 2014) ."},{"key":"ref197\/cit197","unstructured":"Studies found in clinical trials for Lu AE58054:http:\/\/clinicaltrials.gov\/ct2\/results?term=Lu-AE58054+&Search=Search(accessed May 14, 2014) ."},{"key":"ref198\/cit198","unstructured":"Lundbeck\u2019s Lu AE58054 Meets Primary Endpoint in Large Placebo-Controlled Clinical Proof of Concept Study in People with Alzheimer\u2019s Disease. May 29, 2012.http:\/\/investor.lundbeck.com\/releasedetail.cfm?ReleaseID=677436(accessed May 14, 2014) ."},{"key":"ref199\/cit199","unstructured":"Lundbeck and Otsuka Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-On Treatment for Alzheimer\u2019s Disease. October 10, 2013.http:\/\/investor.lundbeck.com\/releasedetail.cfm?ReleaseID=796082(accessed May 14, 2014) ."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/jm5003952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:26:39Z","timestamp":1746231999000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/jm5003952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,3]]},"references-count":199,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2014,9,11]]}},"alternative-id":["10.1021\/jm5003952"],"URL":"https:\/\/doi.org\/10.1021\/jm5003952","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,3]]}}}